Merck Research Laboratories

Latest stories

5d
FOX Business
3 Healthcare Stocks Billionaires Love Right Nowis an often underappreciated asset. In 2013, Merck brought onAmgen's former R&D
3 Healthcare Stocks Billionaires Love Right Now
FOX Business / Posted 5 days ago
is an often underappreciated asset. In 2013, Merck brought onAmgen's former R&D head, Roger Perlmutter.As president of Merck Research Laboratories, Perlmutter expertly shepherded immuno-oncology groundbreaker Keytruda through the regulatory... Read more
5d
FOX Business
3 Healthcare Stocks Billionaires Love Right Nowis an often underappreciated asset. In 2013, Merck brought onAmgen's former R&D
3 Healthcare Stocks Billionaires Love Right Now
FOX Business / Posted 5 days ago
is an often underappreciated asset. In 2013, Merck brought onAmgen's former R&D head, Roger Perlmutter.As president of Merck Research Laboratories, Perlmutter expertly shepherded immuno-oncology groundbreaker Keytruda through the regulatory... Read more
14d
Business Wire
Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meetingthe care of patients with cancer,” said Dr. Roy Baynes, senior vice president a
Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Business Wire / Posted 14 days ago
the care of patients with cancer,” said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. “This analysis reinforces our precision medicine approach in NSCLC to help provide physicians... Read more
2 related stories
17d
Business Wire
Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™for those patients for whom treatment may be challenging,” said Dr. Eliav Barr,
Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Business Wire / Posted 17 days ago
for those patients for whom treatment may be challenging,” said Dr. Eliav Barr, vice president, infectious diseases, Merck Research Laboratories. “These data from Merck’s broad clinical development program underscore the company’s commitment... Read more
19 related stories
19d
News-Medical-Net
SU2C Catalyst program to accelerate research on cancer prevention, detection and treatmentadvocacy and academia," said Dr. Eric Rubin, vice president and therapeutic ar
SU2C Catalyst program to accelerate research on cancer prevention, detection and treatment
News-Medical-Net / Posted 19 days ago
advocacy and academia," said Dr. Eric Rubin, vice president and therapeutic area head, oncology early-stage development, Merck Research Laboratories. "We are proud to be the first to collaborate with SU2C in the development of the Catalyst... Read more

People in this news